Acute Radiation Syndrome
SNBL USA is in a unique position to perform ARS studies, from demonstration of efficacy in representative animal models, to pivotal nonclinical studies under the FDA’s Animal Efficacy Rule.
We are proud of SNBL’s long history of excellence and leadership across our multiple product and service offerings; but more importantly, we benchmark our true success by what we achieve for our customers today and what we do to enable a better future for patients and their families tomorrow.Read More
SNBL USA is committed to providing clients with quality you expect with your preclinical needs. We are committed to providing service you trust with the turnaround you need.
As a drug class, Nucleic Acid-based Therapeutics represents a diverse spectrum of chemistry, constructs, and delivery options.
Blending our strengths, SNBL USA’s laboratory services division represents a powerful resource to extend discovery and development capabilities while still providing superior, individualized service to each client.
We are pleased to announce Christopher Carosino, PhD has recently joined SNBL USA as a Study Director and newest member of the safety assessment team. With more than 10 years of toxicology and research experience, he is a great addition to SNBL USA, complementing existing service and expertise infrastructure. While Dr. Carosino has focused on the field of toxicology over the course of his career training and development, he has overlapping experience with immunology, analytical chemistry, free radical biology, and nanomaterials and targeted expertise in pulmonary and inhalation toxicology....Read More
To our many veterans, active military members and their families: Thank you for your service, devotion and sacrifice. Your courage helps protect and uphold the many freedoms we enjoy as Americans. We are proud of you, and humbly grateful.Read More
The Center for Cancer Research (CCR) of the National Cancer Institute (NCI)/NIH, headed by Dr. Dimiter S. Dimitrov, and SNBL USA recently conducted a pharmacokinetic study with a bi0specific monoclonal antibody targeting a cancer-related protein, IGF2.Read More